Atea Pharmaceuticals(AVIR) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Ef icacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, Mass., May ...